Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Dapagliflozin Propanediol Monohydrate 10mg + Vildagliptin I.P. 100mg Tablets
Therapeutic Category
Antidiabetic, Diabetic
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹299/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Dapa V 10/100 SR Tablet is a dual oral antidiabetic formulation combining the SGLT2 inhibitor Dapagliflozin with the DPP-4 inhibitor Vildagliptin. This combination provides synergistic glycemic control by enhancing insulin secretion and reducing renal glucose reabsorption, leading to increased urinary glucose excretion. It not only improves blood sugar control but also aids in weight management and cardiovascular protection in patients with type 2 diabetes mellitus. The sustained-release formulation ensures prolonged therapeutic action and improved patient adherence.
Common side effects may include urinary tract infections, genital infections, nausea, diarrhea, abdominal discomfort, and increased urination. Rarely, hypoglycemia may occur, especially when combined with other antidiabetic drugs.
Indicated for patients with Type 2 Diabetes Mellitus when diet, exercise, and Metformin monotherapy do not provide adequate glycemic control. Also suitable as part of combination therapy for better blood sugar management.
Not recommended for patients with Type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with renal impairment. Adequate hydration should be maintained to reduce the risk of dehydration.
Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.
Composition : Dapagliflozin 5mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Fenofibrate I.P. 160mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg + Clopidogrel I.P. 75mg + Aspirin I.P. 75mg Capsules
Composition : Atorvastatin Calcium I.P. 80mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Aspirin I.P. 75mg Capsules
Composition : Atorvastatin Calcium I.P. 10mg + Clopidogrel I.P. 75mg Tablets
Composition : Sitagliptin Phosphate I.P. 100mg Tablets
Composition : Sitagliptin Phosphate I.P. 50mg + Metformin HCL I.P. 1000mg Tablets
Composition : Sitagliptin Phosphate I.P. 50mg + Metformin HCL I.P. 500mg Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This antidiabetic combination has strong demand in the diabetes management segment, making it a high-potential product for medical distributors, wholesalers, and pharma franchise partners looking to expand in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes patients requiring dual therapy for better glycemic control, especially in uncontrolled cases. It strengthens their antidiabetic and chronic care portfolio.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Dapagliflozin Propanediol Monohydrate 10mg + Vildagliptin Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, repeat sales, and stable long-term diabetes market growth when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this antidiabetic dual combination can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, bulk procurement, pricing details, and distribution support services.